bnt3214
Advanced Solid Tumor Cancer
BioNTech SEPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
19 Active assets in the Advanced Solid Tumor Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
lm-24c5 LaNova Medicines Limited | Phase 2 | CCC |
Shr-A1811 Sheng Zhang | Phase 2 | CCC |
Capecitabine National University Hospital, Singapore | Phase 1/2 | CCC |
gh55 Suzhou Genhouse Bio Co., Ltd. | Phase 1/2 | CC |
Tislelizumab National University Hospital, Singapore | Phase 1/2 | CC |
View all 19 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →